Soligenix forges new collaboration to develop thermostable biodefense vaccines
This article was originally published in Scrip
Executive Summary
Soligenix, a US development-stage company, has entered into a deal with the Infectious Disease Research Institute (IDRI) of Seattle, Washington, for biodefense vaccine development utilising IDRI’s potent and safe synthetic adjuvants.